Wu, Minghua <br/><br/>
Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.  [electronic resource] 

 -  The American journal of pathology  Feb 2009 
 - 519-33 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1525-2191 
<br/><br/><label>Standard No.: </label>10.2353/ajpath.2009.080574  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adipocytes--cytology<br/>Animals<br/>Antibiotics, Antineoplastic--toxicity<br/>Bleomycin--toxicity<br/>Cell Differentiation--drug effects<br/>Cell Movement--drug effects<br/>Collagen--drug effects<br/>Female<br/>Fibrosis--chemically induced<br/>Flow Cytometry<br/>Fluorescent Antibody Technique<br/>Gene Expression--drug effects<br/>Hypoglycemic Agents--pharmacology<br/>Immunohistochemistry<br/>Inflammation--chemically induced<br/>Mice<br/>Mice, Inbred BALB C<br/>PPAR gamma--drug effects<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Rosiglitazone<br/>Scleroderma, Systemic--chemically induced<br/>Stem Cells--cytology<br/>Thiazolidinediones--pharmacology<br/>Transforming Growth Factor beta1--drug effects